Etripamil

Investigational Therapeutic for
Episodic Cardiovascular Conditions

We’ve designed and are developing the investigational drug, etripamil: a new, potent, and fast-acting calcium channel blocker in the form of a nasal spray to stop PSVT, and other episodic cardiovascular conditions, whenever and wherever they occur.

Milestone, at its founding, sought to create new chemical entities as analogs of known molecular classes with clinically-validated mechanisms of action. Our goal was to preserve the beneficial pharmacology of existing molecules while altering their pharmacokinetic profile with focused medicinal chemistry to produce drugs that are fast-acting and rapidly inactivated in the blood to minimize potential side effects. As a result, we created a series of novel, non-dihydropyridine, L-type calcium channel blockers with the desired properties. Etripamil resulted from this effort as a new chemical entity with the following characteristics:

  • Short half-life: Etripamil is a short-acting drug with a half-life of approximately 30 minutes, meaning it is quickly metabolized by the body, thereby avoiding long-term side effects that can occur with chronic drug therapy
  • Fast onset: Etripamil is designed to be rapidly absorbed into the bloodstream within minutes, allowing it to act quickly on the desired target (electrical conduction system or coronary blood vessels)
  • Convenient administration: We developed etripamil so that it can be conveniently self-administered by patients via a nasal spray device

Currently, etripamil is in Phase 3 development for the treatment of PSVT. We are also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.

We believe that the following qualities of etripamil make it a better treatment for certain transient cardiovascular conditions than current standards of care

We believe that the following qualities of etripamil make it a better treatment for certain transient cardiovascular conditions than current standards of care

Short half-life

Fast onset

Convenient
administration